0QN1 Stock Overview
A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 14.16 |
| 52 Week High | CHF 15.80 |
| 52 Week Low | CHF 7.70 |
| Beta | 0.025 |
| 1 Month Change | 58.74% |
| 3 Month Change | 52.92% |
| 1 Year Change | 58.04% |
| 3 Year Change | -0.28% |
| 5 Year Change | -88.07% |
| Change since IPO | -63.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QN1 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.4% | -2.3% | 0.4% |
| 1Y | 58.0% | -25.3% | 4.8% |
Return vs Industry: 0QN1 exceeded the UK Biotechs industry which returned -25.3% over the past year.
Return vs Market: 0QN1 exceeded the UK Market which returned 4.8% over the past year.
Price Volatility
| 0QN1 volatility | |
|---|---|
| 0QN1 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QN1's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0QN1's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 45 | Dario Eklund | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| 0QN1 fundamental statistics | |
|---|---|
| Market cap | CHF 168.76m |
| Earnings (TTM) | CHF 62.86m |
| Revenue (TTM) | CHF 113.59m |
2.7x
P/E Ratio1.5x
P/S RatioIs 0QN1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QN1 income statement (TTM) | |
|---|---|
| Revenue | CHF 113.59m |
| Cost of Revenue | CHF 6.52m |
| Gross Profit | CHF 107.07m |
| Other Expenses | CHF 44.21m |
| Earnings | CHF 62.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.19 |
| Gross Margin | 94.26% |
| Net Profit Margin | 55.34% |
| Debt/Equity Ratio | 49.2% |
How did 0QN1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 19:36 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurizio Bernasconi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Barbora Blaha | Credit Suisse |